Integration of Health Information Technology and Promotion of Personhood in Family-Centered Dementia Care

October 5, 2023 updated by: Florida International University
Alzheimer's disease and related dementias (ADRD) are leading causes of disability and often result in communication deficits of the person with dementia (PWD) that can complicate ADRD caregiving and clinical care. The research team will work with stakeholders to develop and design a personalized Assistive and Alternative Communication (AAC) device that relies on information technology (IT) and touchscreens to promote communication and personhood for PWD about their care preferences and experiences. This study will integrate the AAC into an existing health IT intervention that already facilitates clinical communication between caregivers and providers of PWD, called CareHeroes (CH). A clinical trial will be conducted to evaluate outcomes of 120 triads (PWD/caregivers/providers) utilizing the CH intervention as an adjunct to care and caregiving for 12 months.

Study Overview

Status

Not yet recruiting

Intervention / Treatment

Detailed Description

The target enrollment for the clinical trial is 120 triads of health care providers, caregivers, and people with dementia (PWD), where 120 unique dyads of caregivers/PWD will participate and healthcare providers will participate in multiple triads. The team plans to enroll 60 triads at each of the two participating clinical sites. Participants will be randomly assigned to either the full intervention or a minimal intervention for a period of 12 months, where they will be asked to communicate clinical and other relevant information with one another as part of regular caregiving and clinical care activities. Several psychosocial outcome variables for providers, caregivers, and PWD will be assessed. We will compare outcomes based on group assignment and different amounts and patterns of use of CH (e.g., minimal/non-users versus frequent users). The primary outcome variables are quality of life for caregivers and PWD.

Study Type

Interventional

Enrollment (Estimated)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Ellen L Brown, EdD,RN,FAAN
  • Phone Number: 305-348-1312
  • Email: ebrown@fiu.edu

Study Contact Backup

  • Name: Nicole Ruggiano, PhD, MSW
  • Phone Number: 205-348-4654
  • Email: nruggiano@ua.edu

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35233
        • UAB Alzheimer's Risk Assessment and Intervention Clinic
        • Contact:
    • Florida
      • Miami, Florida, United States, 33137

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

Caregivers:

  • Regular access to the internet (via computer or smartphone) and telephone
  • 21 years-old or older
  • Providing caregiving activities (Activities of Daily Living and/or Instrumental Activities of Daily Living) for an average of 2 hours or more per day of direct assistance or supervision for a person with ADRD
  • Speak and understand English or Spanish.

Care Recipient:

  • 60 years or older
  • Speak and understand English or Spanish
  • Have an established diagnosis of a Neurocognitive Disorder (Alzheimer's disease, vascular dementia, frontotemporal dementia, Lewy body dementia or Parkinson's disease dementia)
  • Receive a score on the Mini Mental Status Exam of 21 or lower
  • Be able to complete the eligibility vision screen.

Healthcare Providers:

* Provide ongoing healthcare and support services to PWD and their families.

Exclusion Criteria

Caregivers:

  • Provide care to a PWD living in an assisted living facility or nursing home
  • Plan for the PWD to be placed in a long-term care facility during the study period
  • Plan to end their role as caregiver within 6 months of study enrollment
  • Have their own major medical conditions affecting independent functioning (e.g. illness or disability) or cognitive impairment
  • Do not speak and read English or Spanish
  • Have known active suicidal ideation

Care Recipients:

  • Significant visual or hearing impairment (with supports)
  • Known active suicidal ideation
  • Schizophrenia diagnosis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Full Intervention
TRIADs (caregiver, PWD, and provider) randomly assigned to the experimental arm will have access to use CareHeroes AND the newly developed AAC app. Provider will receive information via the AAC app.
CareHeroes (CH) is IT that addresses lack of caregiver support and education about ADRD care that often result in depression, burden, and low caregiving self-efficacy. The CH intervention provides caregivers with electronic and video-based educational materials, links to services, and self-assessments for depression and burden that offer feedback. It also allows the caregiver to assess symptoms of the PWD using clinical assessments, which can be shared with the provider. The clinical trial evaluates the impact of the addition of an AAC interface (e-communication board) to CareHereos that relies on touchscreen technology, pictures, and text to support PWD with communication deficits so that the PWD can engage and communicate about preferences and experiences with the caregiver and provider about their daily and clinical care. The minimal intervention group will only have access to a paper version of the AAC.
Active Comparator: Minimal Intervention
TRIADs (caregiver, PWD, and provider) randomly assigned to the minimal intervention arm will have access to use CareHeroes but only a paper version of the newly developed AAC app.
CareHeroes (CH) is IT that addresses lack of caregiver support and education about ADRD care that often result in depression, burden, and low caregiving self-efficacy. The CH intervention provides caregivers with electronic and video-based educational materials, links to services, and self-assessments for depression and burden that offer feedback. It also allows the caregiver to assess symptoms of the PWD using clinical assessments, which can be shared with the provider. The clinical trial evaluates the impact of the addition of an AAC interface (e-communication board) to CareHereos that relies on touchscreen technology, pictures, and text to support PWD with communication deficits so that the PWD can engage and communicate about preferences and experiences with the caregiver and provider about their daily and clinical care. The minimal intervention group will only have access to a paper version of the AAC.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Quality of Life In Alzheimer's disease- Care Recipient and Caregiver (proxy-interview)
Time Frame: Baseline, 6-months, 12- months
The 13-item QOL-AD scale uses a scale of 1-4 (poor, fair, good, or excellent) to rate a variety of life domains, including the care recipient's physical health, mood, relationships, activities, and ability to complete tasks. The Care Recipient (self-assesses) and caregiver (proxy-interview) complete the QOL-AD.
Baseline, 6-months, 12- months
Change in Perceived Change Index- Caregiver QOL
Time Frame: Baseline, 6-months, 12- months
A 13-item scale that measures caregiver appraisals of self-improvement or decline in distinct areas of well- being. Caregiver indicates whether each item has become worse, stayed the same, or improved in the past month: feeling rested, ability to have time for yourself, and feelings of being upset. The total and subscales (Affect, Somatic, and Ability to Manage)
Baseline, 6-months, 12- months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in PATIENT HEALTH QUESTIONNAIRE (PHQ-9)- Caregiver
Time Frame: Baseline, 6-months, 12- months
The 9-item Patient Health Questionnaire (PHQ-9) includes nine items that correspond to each of the nine symptoms of major depression from the Diagnostic and Statistical Manual of Mental Disorders. The PHQ-9 scores range from 0 to 27 (increasing score correlates with increasing depression severity) and each of the 9 items is scored from 0 to 3, indicating "how often a symptom is bothersome."
Baseline, 6-months, 12- months
Change in The Positive Aspects of Caregiving Scale- Caregiver
Time Frame: Baseline, 6-months, 12- months
The Positive Aspects of Caregiving Scale (Tarlow et al., 2004) assesses positive feelings resulting from care provision among family caregivers of older adults with functional limitations. Each of the 9 items on the scale asks about potential benefits from caregiving for the caregivers.
Baseline, 6-months, 12- months
Change in Zarit Caregiver Burden Inventory-22 items (ZBI-22)- Caregiver
Time Frame: Baseline, 6-months, 12- months
The ZBI-22 (22 items) assesses common stressors experienced by dementia caregivers. A list of statements which reflect how people sometimes feel when taking care of another person are presented and caregivers are queried about how often they felt that way (never, rarely, sometimes, quite frequently, or nearly always).
Baseline, 6-months, 12- months
Change in 12 Item Short-Form Health Survey (SF-12) - Caregiver
Time Frame: Baseline,12- months
The SF-12 is a validated, shortened version of the The RAND Health Care 36-Item Health Survey that includes 7 health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions.
Baseline,12- months
Change in The Revised Memory and Behavior Problems Checklist - Caregiver interviewed about Care Recipient
Time Frame: Baseline,12-months
The Revised Memory and Behavior Problems Checklist, a 24-item caregiver-reported measure of observable memory difficulties and behavior problems in patients along with a parallel assessment of the caregiver's reaction to these behavioral problems. The checklist is a reliable and valid assessment that asks the caregiver to rate the frequency of care recipient problems (0 = never occurred to 4 = daily or more often) within three subscales (i.e., memory-related, depression, and disruptive behaviors). The caregiver rates the frequency of each behavior problem during the past week and his/her reaction to the behavior (i.e., how bothered or upset the caregiver feels when the behavior occurs [0 = not at all to 4 = extremely bothered]).
Baseline,12-months
Change in The Cornell Scale for Depression in Dementia (CSDD)- Care Recipient interviewed, Caregiver Interviewed about Care Recipient
Time Frame: Baseline,12-months
The Cornell Scale for Depression in Dementia (CSDD) is a validated and reliable depression severity measure. The 19-item tool has been validated to rate depression symptoms over the entire range of cognitive impairment. The CSDD is administered via 2 semi-structured interviews: 1 with an informant and 1 with the patient. A final decision regarding the presence or absence of symptoms is achieved by the clinician's judgment and integration of both sets of responses.
Baseline,12-months
Change in Geriatric Depression Scale (GDS-15)- Care Recipient
Time Frame: Baseline,12-months
The 15-item Geriatric Depression Scale (GDS-15) is a depression screening tool developed for use in older adults. It had been validated for community-dwelling, hospitalized, and institutionalized older adults. The GDS-15 has a yes-no format. Scores range from 0 to 15; the higher the score the more likely the individual is experiencing depression.
Baseline,12-months
Change in Partner-Patient Questionnaire for Shared Activities-Caregiver interviewed about relationship with Care Recipient
Time Frame: Baseline, 6 Months, 12 Months
The PPQSA was constructed to measure the extent to which the AD patient's mood and mental state interfered with the patient-partner relationship.
Baseline, 6 Months, 12 Months
Change in Functional Linguistic Communication Inventory (FLCI)- Care Recipient
Time Frame: Baseline, 12 months
Functional Linguistic Communication Inventory (FLCI) is a standardized instrument for evaluating functional communication in persons with moderate and severe dementia. A number of domains assessed included: Greeting and naming, Answering questions, Writing, Sign comprehension, Object-to-picture matching, Word reading and comprehension, Reminiscing, Following commands, Pantomime, Gesture, and Conversation.
Baseline, 12 months
CareHeroes Usage - Links clicked on the app, resources accessed
Time Frame: 6 months
The research team will track user actions ( provider, caregiver, care recipient) on the Web and Android/iphone operating system Apps, such as login, logout, viewing of educational material, taking a health assessment, or contacting the provider.
6 months
Provider Interviews
Time Frame: Baseline, 6 months, 12 months
The research team will conduct interviews with the providers who are participating in the triads. The interview questions will include newly-created closed-ended questions, and open-ended qualitative questions that will assess their perceptions of integrating CareHeroes (CH) into clinical workflow (e.g. acceptability of technology, problems experienced, observed benefits); and how use of CH influenced clinical/shared decision making and clinical care.
Baseline, 6 months, 12 months
CareHeroes Usage- Links clicked on the app, resources accessed
Time Frame: 12 months
The research team will track user actions ( provider, caregiver, care recipient) on the Web and Android/IOS Apps, such as login, logout, viewing of educational material, taking a health assessment, or contacting the provider.
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

February 1, 2024

Primary Completion (Estimated)

February 1, 2025

Study Completion (Estimated)

May 31, 2025

Study Registration Dates

First Submitted

September 21, 2020

First Submitted That Met QC Criteria

September 29, 2020

First Posted (Actual)

October 1, 2020

Study Record Updates

Last Update Posted (Estimated)

October 9, 2023

Last Update Submitted That Met QC Criteria

October 5, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neurocognitive Disorders

3
Subscribe